bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Materials/Methods from Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation
Authors: Wang Jing-Hung , Forterre Alexis V. , Zhao Jinjing , Frimannsson Daniel O. , Delcayre Alain , Antes Travis J. , Efron Bradley , Jeffrey Stefanie S. , Pegram Mark D. , Matin A.C.
Published: April 2023

Methods/legend to Video 1
supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Authors: Delpuech Oona , Rooney Claire , Mooney Lorraine , Baker Dawn , Shaw Robert , Dymond Michael , Wang Dennis , Zhang Pei , Cross Sarah , Veldman-Jones Margaret , Wilson Joanne , Davies Barry R. , Dry Jonathan R. , Kilgour Elaine , Smith Paul D.
Published: April 2023

Cell line panel used to identify AZD4547 dynamic transcript biomarkers.
supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Authors: Delpuech Oona , Rooney Claire , Mooney Lorraine , Baker Dawn , Shaw Robert , Dymond Michael , Wang Dennis , Zhang Pei , Cross Sarah , Veldman-Jones Margaret , Wilson Joanne , Davies Barry R. , Dry Jonathan R. , Kilgour Elaine , Smith Paul D.
Published: April 2023

Differential gene expression and statistical analysis of cell lines treated with AZD4547 or DMSO over time
Supplementary Table S4 from TGFβ-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC
Authors: Siraj Abdul K. , Pratheeshkumar Poyil , Divya Sasidharan Padmaja , Parvathareddy Sandeep Kumar , Bu Rong , Masoodi Tariq , Kong Yan , Thangavel Saravanan , Al-Sanea Nasser , Ashari Luai H. , Abduljabbar Alaa , Al-Homoud Samar , Al-Dayel Fouad , Al-Kuraya Khawla S.
Published: April 2023

Smad4 gene deletion and chromosome 18q monosomy detected in our cohort
Supplementary Table S3 from TGFβ-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC
Authors: Siraj Abdul K. , Pratheeshkumar Poyil , Divya Sasidharan Padmaja , Parvathareddy Sandeep Kumar , Bu Rong , Masoodi Tariq , Kong Yan , Thangavel Saravanan , Al-Sanea Nasser , Ashari Luai H. , Abduljabbar Alaa , Al-Homoud Samar , Al-Dayel Fouad , Al-Kuraya Khawla S.
Published: April 2023

Correlation of Smad4 mutation with clinico-pathological parameters in colorectal carcinoma
Supplemental Table 1 from Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
Authors: Çelik Haydar , Hong Sung-Hyeok , Colón-López Daisy D. , Han Jenny , Kont Yasemin Saygideger , Minas Tsion Z. , Swift Matthew , Paige Mikell , Glasgow Eric , Toretsky Jeffrey A. , Bosch Jürgen , Üren Aykut
Published: April 2023

Initial screening of primary hits for reduced cell motility phenotypes in zebrafish embryonic developmental assays
Supplementary Figure S1 from TGFβ-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC
Authors: Siraj Abdul K. , Pratheeshkumar Poyil , Divya Sasidharan Padmaja , Parvathareddy Sandeep Kumar , Bu Rong , Masoodi Tariq , Kong Yan , Thangavel Saravanan , Al-Sanea Nasser , Ashari Luai H. , Abduljabbar Alaa , Al-Homoud Samar , Al-Dayel Fouad , Al-Kuraya Khawla S.
Published: April 2023

Smad4 alteration in CRC
Supplemental Figure Legends from Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
Authors: Çelik Haydar , Hong Sung-Hyeok , Colón-López Daisy D. , Han Jenny , Kont Yasemin Saygideger , Minas Tsion Z. , Swift Matthew , Paige Mikell , Glasgow Eric , Toretsky Jeffrey A. , Bosch Jürgen , Üren Aykut
Published: April 2023

Supplemental Figure Legends
Supplemental Figure 5 from Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
Authors: Çelik Haydar , Hong Sung-Hyeok , Colón-López Daisy D. , Han Jenny , Kont Yasemin Saygideger , Minas Tsion Z. , Swift Matthew , Paige Mikell , Glasgow Eric , Toretsky Jeffrey A. , Bosch Jürgen , Üren Aykut
Published: April 2023

Representative images of embryos treated with NSC305787 and the hit compounds from MMV400 library are presented with different degrees of phenotypic abnormalities at later stages of embryonic development from 1 to 5 dpf
Supplemental Figure 3 from Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
Authors: Çelik Haydar , Hong Sung-Hyeok , Colón-López Daisy D. , Han Jenny , Kont Yasemin Saygideger , Minas Tsion Z. , Swift Matthew , Paige Mikell , Glasgow Eric , Toretsky Jeffrey A. , Bosch Jürgen , Üren Aykut
Published: April 2023

Cytotoxicity profiles of NSC305787 and the hits from MMV400 library on K12 and K7M2 mouse osteosarcoma cells as generated by xCELLigence RTCA during 48 hr incubation
Supplemental Figure S2 from Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM
Authors: McKinney Andrew , Lindberg Olle R. , Engler Jane R. , Chen Katharine Y. , Kumar Anupam , Gong Henry , Lu Kan V. , Simonds Erin F. , Cloughesy Timothy F. , Liau Linda M. , Prados Michael , Bollen Andrew W. , Berger Mitchel S. , Shieh Joseph T.C. , James C. David , Nicolaides Theodore P. , Yong William H. , Lai Albert , Hegi Monika E. , Weiss William A. , Phillips Joanna J.
Published: April 2023

Supplemental Figure S2 shows that DEAB inhibits erlotinib-induced invasion and ALDH1A1 expression in parental CSCs.
Supplemental Figure 1 from Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
Authors: Çelik Haydar , Hong Sung-Hyeok , Colón-López Daisy D. , Han Jenny , Kont Yasemin Saygideger , Minas Tsion Z. , Swift Matthew , Paige Mikell , Glasgow Eric , Toretsky Jeffrey A. , Bosch Jürgen , Üren Aykut
Published: April 2023

Chemical structures of the small molecule inhibitor of ezrin, NSC305787, and quinoline-containing antimalarial agents
Supplementary Figure S3 from Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma
Authors: Yu Yang , Zhao Yanling , Fan Yihui , Chen Zhenghu , Li Hui , Lu Jiaxiong , Guo Kevin , Woodfield Sarah E. , Vasudevan Sanjeev A. , Yang Jianhua , Nuchtern Jed G.
Published: April 2023

USP14 inhibitor b-AP15 inhibits colony formation in neuroblastoma cells.
Supplementary Figure S5 from A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo
Authors: Mäemets-Allas Kristina , Viil Janeli , Jaks Viljar
Published: April 2023

ALT and AST values measured from blood serum of mice used in xenograft experiment
Supplementary Figure S3 from A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo
Authors: Mäemets-Allas Kristina , Viil Janeli , Jaks Viljar
Published: April 2023

NSC156529 interacted with PDPK1 and AKT1
Supplementary Figure S1 from Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma
Authors: Yu Yang , Zhao Yanling , Fan Yihui , Chen Zhenghu , Li Hui , Lu Jiaxiong , Guo Kevin , Woodfield Sarah E. , Vasudevan Sanjeev A. , Yang Jianhua , Nuchtern Jed G.
Published: April 2023

The effect of USP14 inhibition on cell proliferation in non-tumor cells.
Supplementary Table S1 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Table S1 shows the gene and pathway analysis of genes regulated by NCGC00117362 in Kuramochi ovarian cancer cells.
Supplementary Methods from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Methods describes the Proteomics and Gene Expression Analysis Methods and References.
Supplementary Figure S9 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Figure S9 shows the testing of SAR analogs of NCGC00117362 in secondary confirmatory assays.
Supplementary Materials and Methods from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
Authors: Sidarovich Viktoryia , De Mariano Marilena , Aveic Sanja , Pancher Michael , Adami Valentina , Gatto Pamela , Pizzini Silvia , Pasini Luigi , Croce Michela , Parodi Federica , Cimmino Flora , Avitabile Marianna , Emionite Laura , Cilli Michele , Ferrini Silvano , Pagano Aldo , Capasso Mario , Quattrone Alessandro , Tonini Gian Paolo , Longo Luca
Published: April 2023

Spheroid image analysis, 3D invasion image analysis and antibodies list.
Supplementary Figure S4 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Figure S4 shows the activity of non-lead compounds in secondary biological assays.
Supplementary Figures S1-S7 from Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Authors: Kodama Tatsushi , Kochi Yu , Nakai Waka , Mizuno Hideaki , Baba Takeshi , Habu Kiyoshi , Sawada Noriaki , Tsunoda Hiroyuki , Shima Takahiro , Miyawaki Kohta , Kikushige Yoshikane , Mori Yasuo , Miyamoto Toshihiro , Maeda Takahiro , Akashi Koichi
Published: April 2023

Supplementary Figures S1-S7. Figure S1: Cell surface expression of GPRC5D on malignant cells from multiple myeloma (patient number: MM#2 to MM#11 in Supplementary Table S1). Figure S2: Cell surface expression of GPRC5D on cancer cell lines and cytotoxicity of GPRC5D TRABs when co-culturing GPRC5D-expressing NCI-H929 cells without PBMC. Figure S3: Cytotoxicity of GPRC5D TRABs when co-culturing GPRC5D-expressing NCI-H929 cells with CD4+ T cells or CD8+ T cells. Figure S4: Antitumor activity and plasma concentrations of GPA0039 TRAB in mouse models with NCI-H929 tumors. Figure S5: T-cell activation of GPRC5D TRABs after co-culturing with GloResponse{trade mark, serif} NFAT-luc2 Jurkat cells and NCI-H929 cells or Human Bone Marrow CD34+ cells (StemCell Technologies) from two different donors. Figure S6: mRNA expression (TPM value) of GPRC5D and BCMA using the GTEx sample set. Figure S7: Binding activity of 100 nM of anti-GPRC5D antibodies on CHO cells expressing cynomolgus monkey GPRC5D.
Supplementary Tables S1-S3; Supplementary Figures S1-S6 including legends; and Supplementary References from A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition
Authors: Trenner Anika , Godau Julia , Sartori Alessandro A.
Published: April 2023

Table S1: Primary antibodies; Table S2: Secondary antibodies; Table S3: siRNA oligos; Figure S1, related to Figure 1: BRC4 peptide inhibits RAD51 binding to BRCA2 and RAD51 self-oligomerization; Figure S2; related to Figure 2: Efficient cellular uptake of TAMRA- and Fluorescein-labeled R9-BRC4 peptides; Figure S3, related to Figure 4: BRC4 peptide suppresses DNA damage-induced RAD51 foci formation in U2OS cells; Figure S4, related to Figure 5: BRC4 peptide does not affect bulk DNA replication; Figure S5, related to Figure 6: BRC4 peptide confers DNA damage hypersensitivity; Figure S6, related to Figure 6: BRC4 peptide confers olaparib hypersensitivity in cancer cell lines.
Supplementary Fig. S5 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
Authors: Dawson John C. , Serrels Bryan , Byron Adam , Muir Morwenna T. , Makda Ashraff , García-Muñoz Amaya , von Kriegsheim Alex , Lietha Daniel , Carragher Neil O. , Frame Margaret C.
Published: April 2023

Quantification of YAP localization in esophageal cell lines.
Supplementary Table 3 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Authors: Rhyasen Garrett W. , Hattersley Maureen M. , Yao Yi , Dulak Austin , Wang Wenxian , Petteruti Philip , Dale Ian L. , Boiko Scott , Cheung Tony , Zhang Jingwen , Wen Shenghua , Castriotta Lillian , Lawson Deborah , Collins Michael , Bao Larry , Ahdesmaki Miika J. , Walker Graeme , O'Connor Greg , Yeh Tammie C. , Rabow Alfred A. , Dry Jonathan R. , Reimer Corinne , Lyne Paul , Mills Gordon B. , Fawell Stephen E. , Waring Michael J. , Zinda Michael , Clark Edwin , Chen Huawei
Published: April 2023

Protein modulation by AZD5153 in hematological cell lines
Supplementary Fig. S1 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
Authors: Dawson John C. , Serrels Bryan , Byron Adam , Muir Morwenna T. , Makda Ashraff , García-Muñoz Amaya , von Kriegsheim Alex , Lietha Daniel , Carragher Neil O. , Frame Margaret C.
Published: April 2023

Proteomic analysis of FAK protein complexes and turnover.
Supplementary Data from Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma
Authors: Lin Cho-Hao , Elkholy Khadija H. , Wani Nissar A. , Li Ding , Hu Peng , Barajas Juan M. , Yu Lianbo , Zhang Xiaoli , Jacob Samson T. , Khan Wasif N. , Bai Xue-Feng , Noonan Anne M. , Ghoshal Kalpana
Published: April 2023

Supplementary figures and tables
Supplementary Figures S1-S6 and Supplementary Table S1 from Anticancer Activity of ZnO Nanoparticles against Human Small-Cell Lung Cancer in an Orthotopic Mouse Model
Authors: Tanino Ryosuke , Amano Yoshihiro , Tong Xuexia , Sun Rong , Tsubata Yukari , Harada Mamoru , Fujita Yasuhisa , Isobe Takeshi
Published: April 2023

Supplementary Figure S1 - Evaluation of other batches of ZnO nanoparticles (ZnO_71.9). Supplementary Figure S2 - Background level of fluorescence of N417, H82, OUS-11, and BEAS-2B cells treated with 25 μM Zinquin ethyl ester. Supplementary Figure S3 - The comparison of gene expression in antioxidants between small-cell lung cancer (SCLC) and normal cells. Supplementary Figure S4 - Data of ZnO-treated mouse after orthotopically injection. Supplementary Figure S5 - Tumor metastasis in vehicle-treated mice after N417 orthotopically injection. Supplementary Figure S6 - Schematic illustration of ROS productions induced by ZnO nanoparticles. Supplementary Table S1 -The sequences for primers used in quantitative PCR.
Supplemental Figure 5 from ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
Authors: Gao Ge , Zhang Tianshun , Wang Qiushi , Reddy Kanamata , Chen Hanyong , Yao Ke , Wang Keke , Roh Eunmiri , Zykova Tatyana , Ma Weiya , Ryu Joohyun , Curiel-Lewandrowski Clara , Alberts David , Dickinson Sally E. , Bode Ann M. , Xing Ying , Dong Zigang
Published: April 2023

ADA-07 significantly suppresses SUV-induced skin carcinogenesis in SKH-1 hairless mice (early-stage prevention). A, average body weight of SKH-1 hairless mice. Mice were weighed once a week until the end of the study at week 28. B, external appearance of tumors. SKH-1 hairless mice were treated as described in Materials and Methods. The mice in the control groups (n = 9) received no vehicle/no SUV (n = 3), vehicle/no SUV (n = 3), or 1 mg ADA-07/no SUV (n = 3), respectively. The mice in the SUV treated group received SUV only (n = 12) and the mice in the vehicle/SUV-treated group (n = 12) were treated with oil-in-water emulsion cream before SUV exposure. The mice in the 0.1 mg/SUV or 1 mg/SUV groups (n = 12 each) received treatment with ADA-07 (0.1 or 1 mg, respectively) before SUV exposure. The frequency of irradiation was set at 3 times a week for 15 weeks. The respective doses of oil-in-water emulsion cream or ADA-07 were applied topically to the dorsal area. Tumor incidence and multiplicity were recorded weekly until the end of the experiment at week 28.
Supplemental Figure 4 from ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
Authors: Gao Ge , Zhang Tianshun , Wang Qiushi , Reddy Kanamata , Chen Hanyong , Yao Ke , Wang Keke , Roh Eunmiri , Zykova Tatyana , Ma Weiya , Ryu Joohyun , Curiel-Lewandrowski Clara , Alberts David , Dickinson Sally E. , Bode Ann M. , Xing Ying , Dong Zigang
Published: April 2023

The binding between ADA-07 and TOPK is illustrated by Maestro in the Schrödinger Suite. The binding model shows that the hydrogen atom (white color) of glycine binds with oxygen (red color) and nitrogen (blue color) of ADA-07 to form hydrogen bonds. The oxygen atom of glycine binds with hydrogen of ADA-07 to form a hydrogen bond.
Supplemental Figure 3 from ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
Authors: Gao Ge , Zhang Tianshun , Wang Qiushi , Reddy Kanamata , Chen Hanyong , Yao Ke , Wang Keke , Roh Eunmiri , Zykova Tatyana , Ma Weiya , Ryu Joohyun , Curiel-Lewandrowski Clara , Alberts David , Dickinson Sally E. , Bode Ann M. , Xing Ying , Dong Zigang
Published: April 2023

Measurement of ADA-07 absorbance by spectrophotometer. Absorbance wavelengths of ADA-07 were scanned using a Beckman DU®800 spectrophotometer.
Supplementary Figure S3 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

AZD8835 induced apoptosis in MCF7 measured by gamma-H2AX and PARP cleavage.
Supplementary Data File 1 from In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Authors: Hughes Paul E. , Rex Karen , Caenepeel Sean , Yang Yajing , Zhang Yihong , Broome Martin A. , Kha Hue T. , Burgess Teresa L. , Amore Benny , Kaplan-Lefko Paula J. , Moriguchi Jodi , Werner Jonathan , Damore Michael A. , Baker Daniel , Choquette Deborah M. , Harmange Jean-Christophe , Radinsky Robert , Kendall Richard , Dussault Isabelle , Coxon Angela
Published: April 2023

AMG 337 KINOME scan binding data
Supplementary Table S2 from APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer
Authors: Tanaka Noritaka , Mashima Tetsuo , Mizutani Anna , Sato Ayana , Aoyama Aki , Gong Bo , Yoshida Haruka , Muramatsu Yukiko , Nakata Kento , Matsuura Masaaki , Katayama Ryohei , Nagayama Satoshi , Fujita Naoya , Sugimoto Yoshikazu , Seimiya Hiroyuki
Published: April 2023

Multiple regression analysis of tankyrase inhibitor sensitivities and genetic mutations in colorectal cancer cell lines
Figure S1 from In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models
Authors: Cornillie Jasmien , Wozniak Agnieszka , Pokreisz Peter , Casazza Andrea , Vreys Lise , Wellens Jasmien , Vanleeuw Ulla , Gebreyohannes Yemarshet K. , Debiec-Rychter Maria , Sciot Raf , Hompes Daphne , Schöffski Patrick
Published: April 2023

H&E stainings of the original patient samples (200x) and representative images of H&E staining (200x), MDM2 or EMA immunostaining (400x) and FISH (1000x) in UZLX-STS3, UZLX-STS5 and UZLX-STS7. On MDM2 FISH, green signals identify the chromosome 12 centromere, while the red cluster of signals represents the amplified MDM2. On SS18 FISH, the red and green signals identify probes flanking the SS18 gene on chromosome 18. In case of an SS18 rearrangement, a split signal between the red and green probe is observed. EMA: epithelial membrane antigen; FISH: fluorescence in situ hybridization; H&E: hematoxylin and eosin; IHC: immunohistochemistry; MDM2: mouse double minute 2 homolog.
Figure S3 from The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In Vivo
Authors: De Marco Carmela , Rinaldo Nicola , De Vita Fernanda , Forzati Floriana , Caira Elvira , Iovane Valentina , Paciello Orlando , Montanaro Donatella , D'Andrea Sara , Baldassarre Gustavo , Papparella Serenella , Malanga Donatella , Baldi Alfonso , Viglietto Giuseppe
Published: April 2023

The figure shows the immunostaining analysis of Ki67 in organs from Cdkn1b T197A/T197A mice treated with Vehicle or Bortezomib
Supplementary Figure S2 from Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth
Authors: Spyrou Argyris , Kundu Soumi , Haseeb Lulu , Yu Di , Olofsson Tommie , Dredge Keith , Hammond Edward , Barash Uri , Vlodavsky Israel , Forsberg-Nilsson Karin
Published: April 2023

Effects of PG545 on ERK and AKT phosphorylation in PFSK-1 and D324 tumor cells.
Figure S1 from The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In Vivo
Authors: De Marco Carmela , Rinaldo Nicola , De Vita Fernanda , Forzati Floriana , Caira Elvira , Iovane Valentina , Paciello Orlando , Montanaro Donatella , D'Andrea Sara , Baldassarre Gustavo , Papparella Serenella , Malanga Donatella , Baldi Alfonso , Viglietto Giuseppe
Published: April 2023

The figure illustrates the construct used for the generation of Cdkn1b T197A/T197A mice and the subsequent genotype validation.
Supplementary Data from Antitumor Synergism and Enhanced Survival with a Tumor Vasculature–Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide
Authors: Krais John J. , Virani Needa , McKernan Patrick H. , Nguyen Quang , Fung Kar-Ming , Sikavitsas Vassilios I. , Kurkjian Carla , Harrison Roger G.
Published: April 2023

This file contains includes 9 figures of supplementary data (S1-S9) and a description of live cell microscopy and the assessment of synergism for the combination therapies.
Figure S6 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
Authors: Zanini Elisa , Louis Louay S. , Antony Jane , Karali Evdoxia , Okon Imoh S. , McKie Arthur B. , Vaughan Sebastian , El-Bahrawy Mona , Stebbing Justin , Recchi Chiara , Gabra Hani
Published: April 2023

Immunohistochemistry staining for OPCML in breast cancer cases
Supplementary Tables S1-S3 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Authors: Totiger Tulasigeri M. , Srinivasan Supriya , Jala Venkatakrishna R. , Lamichhane Purushottam , Dosch Austin R. , Gaidarski Alexander A. , Joshi Chandrashekhar , Rangappa Shobith , Castellanos Jason , Vemula Praveen Kumar , Chen Xi , Kwon Deukwoo , Kashikar Nilesh , VanSaun Michael , Merchant Nipun B. , Nagathihalli Nagaraj S.
Published: April 2023

Supplementary Tables shows primary antibodies used for Western blot, IHC, Flow Cytometry and IC50 values for Uro A.
Figure S5 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
Authors: Zanini Elisa , Louis Louay S. , Antony Jane , Karali Evdoxia , Okon Imoh S. , McKie Arthur B. , Vaughan Sebastian , El-Bahrawy Mona , Stebbing Justin , Recchi Chiara , Gabra Hani
Published: April 2023

High expression of OPCML in HER2-positive Breast Cancer samples is associated with better response to lapatinib
Figure S3 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
Authors: Zanini Elisa , Louis Louay S. , Antony Jane , Karali Evdoxia , Okon Imoh S. , McKie Arthur B. , Vaughan Sebastian , El-Bahrawy Mona , Stebbing Justin , Recchi Chiara , Gabra Hani
Published: April 2023

SKOV3, OV90 and SKBR3 cells were virally transduced to express OPCML
Supplementary Figure S5 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Authors: Totiger Tulasigeri M. , Srinivasan Supriya , Jala Venkatakrishna R. , Lamichhane Purushottam , Dosch Austin R. , Gaidarski Alexander A. , Joshi Chandrashekhar , Rangappa Shobith , Castellanos Jason , Vemula Praveen Kumar , Chen Xi , Kwon Deukwoo , Kashikar Nilesh , VanSaun Michael , Merchant Nipun B. , Nagathihalli Nagaraj S.
Published: April 2023

Supplementary Figure S5 shows densitometry analyses of pAKT and pP70S6K in HPNE and HPNE-KRAS cells.
Supplementary Figures S1-S4 and Tables S1-S2 from Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A–Based Immunotoxins
Authors: Liu Xiufen , Müller Fabian , Wayne Alan S. , Pastan Ira
Published: April 2023

Fig S1. H89 increased ADP-ribosylation and MCL-1 degradation in SEM cells Fig S2. Combination of RIT and H89 lowers MCL1 and induces PARP-cleavage Fig S3. PKA regulator, S6K1-, or ROCK2-inhibitor show little change in LMB-11 activity Fig S4. Combination of LMB-11 and S6K1 inhibitor PF4708671 enhances MCL1 degradation but not ADP-ribosylation Table S1. Cytotoxic activity (IC50) of immunotoxins with and without H89 Table S2. In vitro screening for H89 inhibited kinases
Supplementary Figure S1 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Authors: Totiger Tulasigeri M. , Srinivasan Supriya , Jala Venkatakrishna R. , Lamichhane Purushottam , Dosch Austin R. , Gaidarski Alexander A. , Joshi Chandrashekhar , Rangappa Shobith , Castellanos Jason , Vemula Praveen Kumar , Chen Xi , Kwon Deukwoo , Kashikar Nilesh , VanSaun Michael , Merchant Nipun B. , Nagathihalli Nagaraj S.
Published: April 2023

Supplementary Figure S1 shows Uro B and Uro C treatment on PDAC cell viability.
Supplementary figure S7 from Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism
Authors: Wiedmer Tabea , Blank Annika , Pantasis Sophia , Normand Lea , Bill Ruben , Krebs Philippe , Tschan Mario P. , Marinoni Ilaria , Perren Aurel
Published: April 2023

LMP in QGP1 cells and autophagic flux calculation upon treatment with autophagy inhibitors
Supplementary Figure Legends from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

Supplementary Figure Legends
Supplementary figure S6 from Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism
Authors: Wiedmer Tabea , Blank Annika , Pantasis Sophia , Normand Lea , Bill Ruben , Krebs Philippe , Tschan Mario P. , Marinoni Ilaria , Perren Aurel
Published: April 2023

Apoptosis induction of combination treatment in BON1 cells
Supplementary figure S2 from Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism
Authors: Wiedmer Tabea , Blank Annika , Pantasis Sophia , Normand Lea , Bill Ruben , Krebs Philippe , Tschan Mario P. , Marinoni Ilaria , Perren Aurel
Published: April 2023

Autophagy in PanNET cell lines and human PanNET tissue
Supplemental Tables 1-7 from Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Authors: Datta Jharna , Damodaran Senthilkumar , Parks Hannah , Ocrainiciuc Cristina , Miya Jharna , Yu Lianbo , Gardner Elijah P. , Samorodnitsky Eric , Wing Michele R. , Bhatt Darshna , Hays John , Reeser Julie W. , Roychowdhury Sameek
Published: April 2023

Supplemental Table 1. Expression of FGFR1 and FGFR3 in different cell lines; Supplemental Table 2. Normalized Reverse Phase Protein Array Results for DMS114; Supplemental Table 3. Normalized Reverse Phase Protein Array Results for RT112; Supplemental Table 4. Significantly up-/down-regulated proteins in resistant DMS114 cell line compared with the control; Supplemental Table 5. Significantly up-/down-regulated proteins in resistant RT112 cell line compared with the control; Supplemental Table 6. Expression of EGFR, ERBB2 and MET genes in resistant FGFR cell lines; Supplemental Table 7. Expression of Akt isoforms in different cell lines.
Supplementary Tables 1-2 and Supplementary Figures S1-S5 and legends from Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152
Authors: Wang Yu , Wang Sinan , Wu Yansheng , Ren Yu , Li Zhaoqing , Yao Xiaofeng , Zhang Chao , Ye Na , Jing Chao , Dong Jiabin , Zhang Kailiang , Sun Shanshan , Zhao Minghui , Guo Wenyu , Qu Xin , Qiao Yu , Chen Haiying , Kong Lingping , Jin Rui , Wang Xudong , Zhang Lun , Zhou Jia , Shen Qiang , Zhou Xuan
Published: April 2023

Supplementary Table 1. List of primers and oligos used in this investigation; Supplementary Table 2 Primary antibodies used in this investigation; Supplementary Figure S1. HJC0152 exerts antitumor effect against HNSCC cell lines via regulating STAT3; Supplementary Figure S2. HJC0152 blocks nuclear translocation of p-STAT3 and β-catenin; Supplementary Figure S3. HJC0152 suppresses invasion and migration in HNSCC cell lines; Supplementary Figure S4. HJC0152 regulates the activity of miR-21/β-catenin axis; Supplementary Figure S5. VHL abrogation dramatically counteracts the impact of HJC0152 in vitro.
Supplemental Figure 4 from Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Authors: Datta Jharna , Damodaran Senthilkumar , Parks Hannah , Ocrainiciuc Cristina , Miya Jharna , Yu Lianbo , Gardner Elijah P. , Samorodnitsky Eric , Wing Michele R. , Bhatt Darshna , Hays John , Reeser Julie W. , Roychowdhury Sameek
Published: April 2023

Heat maps show RPPA protein changes in pair-matched control and BGJ398-resistant cell lines.
Figure S8 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Figure S8 shows that the body weight of AML-bearing mice is not affected by Debio 0617B.
Figure S3 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Figure S3 shows response of MOLM-13 cells to Debio 0617B after silencing of STAT3 and STAT5.
Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Authors: Punnoose Elizabeth A. , Leverson Joel D. , Peale Franklin , Boghaert Erwin R. , Belmont Lisa D. , Tan Nguyen , Young Amy , Mitten Michael , Ingalla Ellen , Darbonne Walter C. , Oleksijew Anatol , Tapang Paul , Yue Peng , Oeh Jason , Lee Leslie , Maiga Sophie , Fairbrother Wayne J. , Amiot Martine , Souers Andrew J. , Sampath Deepak
Published: April 2023

Correlation of mRNA expression of BCL2 family members and sensitivity to venetoclax or navitoclax in HMCLs
Figure S5 from Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design
Authors: Sootome Hiroshi , Miura Akihiro , Masuko Norio , Suzuki Takamasa , Uto Yoshihiro , Hirai Hiroshi
Published: April 2023

TAS-119 was compared to MK-5108 in in vivo HeLa-luc xenograft model.
Figure S3 from Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design
Authors: Sootome Hiroshi , Miura Akihiro , Masuko Norio , Suzuki Takamasa , Uto Yoshihiro , Hirai Hiroshi
Published: April 2023

Four hours after oral administration of TAS-119 HCl salt, phosphorylation of histone H3 in tumor (a) and skin (b) tissues was monitored using western blotting.
Supplementary Figure 2 from A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment
Authors: Kuang Zhihui , Pu Pu , Wu Min , Wu Zhihai , Wang Li , Li Yiming , Zhang Shaofei , Jing Hua , Wu Weiwei , Chen Bingliang , Liu Junjian
Published: April 2023

Cell based binding
Table S4 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Authors: Strickler John H. , LoRusso Patricia , Salgia Ravi , Kang Yoon-Koo , Yen Chia Jui , Lin Chia-Chi , Ansell Peter , Motwani Monica , Wong Shekman , Yue Huibin , Wang Lan , Reilly Edward , Afar Daniel , Naumovski Louie , Ramanathan Ramesh K.
Published: April 2023

Additional details on TEAEs for all doses in the combination therapy cohort
Supplementary Material from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Authors: Thakkar Dipti , Sancenon Vicente , Taguiam Marvin M. , Guan Siyu , Wu Zhihao , Ng Eric , Paszkiewicz Konrad H. , Ingram Piers J. , Boyd-Kirkup Jerome D.
Published: April 2023

Supplementary Methods with References, Supplementary Figure Legends, and list of Supplementary Tables
Supplementary Figure 3 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Authors: Thakkar Dipti , Sancenon Vicente , Taguiam Marvin M. , Guan Siyu , Wu Zhihao , Ng Eric , Paszkiewicz Konrad H. , Ingram Piers J. , Boyd-Kirkup Jerome D.
Published: April 2023

10D1F demonstrates superior inhibition of cancer cell line proliferation by potently inhibiting downstream signaling through the PI3K pathway in additional cancer cell lines
Supplemental Table 2 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Authors: Thakkar Dipti , Sancenon Vicente , Taguiam Marvin M. , Guan Siyu , Wu Zhihao , Ng Eric , Paszkiewicz Konrad H. , Ingram Piers J. , Boyd-Kirkup Jerome D.
Published: April 2023

Supplemental Table 2 - Summary of protein and gene expression data of HER family molecules, and their ligands, for the cancer cell lines used in this study
Supplemental Table 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Authors: Thakkar Dipti , Sancenon Vicente , Taguiam Marvin M. , Guan Siyu , Wu Zhihao , Ng Eric , Paszkiewicz Konrad H. , Ingram Piers J. , Boyd-Kirkup Jerome D.
Published: April 2023

Supplemental Table 1 - Summary of the published functional mechanisms of action for anti-HER3 neutralizing antibodies in development
Figure S4 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
Authors: Xie Binbin , Wan Jianqin , Chen Xiaona , Han Weidong , Wang Hangxiang
Published: April 2023

Supplementary Figure S4. Cellular uptake of dCTX NPs in Hela/DTX cells. The cells were treated with free DiI and DiI@dCTX NPs and visualized by confocal laser scanning microscope (CLSM). The red fluorescent signal represented the DiI dye in cells. The cell lysosomes and nuclei were stained with LysoTracker Green NDN-26 (green) and Hoechst 33342 (blue), respectively. The scale bars represent 20 μm in length.
Fig. S4 from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Authors: Pucciarelli Daniela , Angus Steven P. , Huang Benjamin , Zhang Chi , Nakaoka Hiroki J. , Krishnamurthi Ganesh , Bandyopadhyay Sourav , Clapp D. Wade , Shannon Kevin , Johnson Gary L. , Nakamura Jean L.
Published: April 2023

Supplementary Figure 4
Fig. S2 from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Authors: Pucciarelli Daniela , Angus Steven P. , Huang Benjamin , Zhang Chi , Nakaoka Hiroki J. , Krishnamurthi Ganesh , Bandyopadhyay Sourav , Clapp D. Wade , Shannon Kevin , Johnson Gary L. , Nakamura Jean L.
Published: April 2023

Supplementary Figure 2
Supplementary Data TS4 from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Authors: Rogers Oliver C. , Antony Lizamma , Levy Oren , Joshi Nitin , Simons Brian W. , Dalrymple Susan L. , Rosen D. Marc , Pickering Andrew , Lan Haoyue , Kuang Heidi , Ranganath Sudhir H. , Zheng Lei , Karp Jeffrey M. , Howard S. Peter , Denmeade Samuel R. , Isaacs John T. , Brennen W. Nathaniel
Published: April 2023

Tbl S4
Supplementary Data TS1 from Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Authors: Rogers Oliver C. , Antony Lizamma , Levy Oren , Joshi Nitin , Simons Brian W. , Dalrymple Susan L. , Rosen D. Marc , Pickering Andrew , Lan Haoyue , Kuang Heidi , Ranganath Sudhir H. , Zheng Lei , Karp Jeffrey M. , Howard S. Peter , Denmeade Samuel R. , Isaacs John T. , Brennen W. Nathaniel
Published: April 2023

Tbl S1
Supplementary Table S4 from Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo
Authors: Ohol Yamini M. , Sun Michael T. , Cutler Gene , Leger Paul R. , Hu Dennis X. , Biannic Berenger , Rana Payal , Cho Cynthia , Jacobson Scott , Wong Steve T. , Sanchez Jerick , Shah Niket , Pookot Deepa , Abraham Betty , Young Kyle , Suthram Silpa , Marshall Lisa A. , Bradford Delia , Kozon Nathan , Han Xinping , Okano Akinori , Maung Jack , Colas Christophe , Schwarz Jacob , Wustrow David , Brockstedt Dirk G. , Kassner Paul D.
Published: April 2023

Genes whose expression is significantly altered upon USP7 inhibitor treatment of H526 cells.
Supplementary Table S3 from Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo
Authors: Ohol Yamini M. , Sun Michael T. , Cutler Gene , Leger Paul R. , Hu Dennis X. , Biannic Berenger , Rana Payal , Cho Cynthia , Jacobson Scott , Wong Steve T. , Sanchez Jerick , Shah Niket , Pookot Deepa , Abraham Betty , Young Kyle , Suthram Silpa , Marshall Lisa A. , Bradford Delia , Kozon Nathan , Han Xinping , Okano Akinori , Maung Jack , Colas Christophe , Schwarz Jacob , Wustrow David , Brockstedt Dirk G. , Kassner Paul D.
Published: April 2023

Gene sets significantly upregulated upon USP7 inhibitor treatment of H526 cells.
Figure S4 from PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation
Authors: Michmerhuizen Anna R. , Pesch Andrea M. , Moubadder Leah , Chandler Benjamin C. , Wilder-Romans Kari , Cameron Meleah , Olsen Eric , Thomas Dafydd G. , Zhang Amanda , Hirsh Nicole , Ritter Cassandra L. , Liu Meilan , Nyati Shyam , Pierce Lori J. , Jagsi Reshma , Speers Corey
Published: April 2023

Total PARP1 levels do not change with treatment but PAR levels are decreased by PARPi. Total levels of PARP1 were assessed in tumors from mice treated with olaparib. Olaparib treatment did not affect PARP1 protein expression by IHC in olaparib-alone, RT alone, or combination treated animals (A). Representative images of PARP1 staining are shown for all treatment conditions (B). PAR levels were, however, significantly decreased in the animals treated with olaparib alone (C). Representative images of PAR staining are shown for all treatment conditions (D). (NS: not significant, * p < 0.05)
Table S5 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Authors: Morschhauser Franck , Machiels Jean-Pascal , Salles Gilles , Rottey Sylvie , Rule Simon A.J. , Cunningham David , Peyrade Frederic , Fruchart Christophe , Arkenau Hendrik-Tobias , Genvresse Isabelle , Liu Li , Köchert Karl , Shen Kui , Kneip Christoph , Peña Carol E. , Grevel Joachim , Zhang Jun , Cisternas Galia , Reschke Susanne , Granvil Camille , Awada Ahmad
Published: April 2023

shows an estimation of copanlisib exposure variables following first infusion or at first tumor size assessment
Supplemental Figure 3 from Inhibition of Lysosomal Function Mitigates Protective Mitophagy and Augments Ceramide Nanoliposome–Induced Cell Death in Head and Neck Squamous Cell Carcinoma
Authors: Shaw Jeremy J.P. , Boyer Timothy L. , Venner Emily , Beck Patrick J. , Slamowitz Tristen , Caste Tara , Hickman Alexandra , Raymond Michael H. , Costa-Pinheiro Pedro , Jameson Mark J. , Fox Todd E. , Kester Mark
Published: April 2023

Methylpyruvate Partially Rescues from CNL+CQ-driven Autophagic/Mitophagic Response in UNC-10 Cells
Table S3 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Authors: Morschhauser Franck , Machiels Jean-Pascal , Salles Gilles , Rottey Sylvie , Rule Simon A.J. , Cunningham David , Peyrade Frederic , Fruchart Christophe , Arkenau Hendrik-Tobias , Genvresse Isabelle , Liu Li , Köchert Karl , Shen Kui , Kneip Christoph , Peña Carol E. , Grevel Joachim , Zhang Jun , Cisternas Galia , Reschke Susanne , Granvil Camille , Awada Ahmad
Published: April 2023

shows plasma biomarkers with decreased levels compared to baseline following copanlisib infusion
Table S2 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Authors: Morschhauser Franck , Machiels Jean-Pascal , Salles Gilles , Rottey Sylvie , Rule Simon A.J. , Cunningham David , Peyrade Frederic , Fruchart Christophe , Arkenau Hendrik-Tobias , Genvresse Isabelle , Liu Li , Köchert Karl , Shen Kui , Kneip Christoph , Peña Carol E. , Grevel Joachim , Zhang Jun , Cisternas Galia , Reschke Susanne , Granvil Camille , Awada Ahmad
Published: April 2023

shows baseline PI3K isoform and PTEN data for lymphoma and solid tumor cohorts
Table S1 from On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Authors: Morschhauser Franck , Machiels Jean-Pascal , Salles Gilles , Rottey Sylvie , Rule Simon A.J. , Cunningham David , Peyrade Frederic , Fruchart Christophe , Arkenau Hendrik-Tobias , Genvresse Isabelle , Liu Li , Köchert Karl , Shen Kui , Kneip Christoph , Peña Carol E. , Grevel Joachim , Zhang Jun , Cisternas Galia , Reschke Susanne , Granvil Camille , Awada Ahmad
Published: April 2023

shows an overview of patient disposition
Supplementary Movie M5 from Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Authors: Vijayaraghavan Smruthi , Lipfert Lorraine , Chevalier Kristen , Bushey Barbara S. , Henley Benjamin , Lenhart Ryan , Sendecki Jocelyn , Beqiri Marilda , Millar Hillary J. , Packman Kathryn , Lorenzi Matthew V. , Laquerre Sylvie , Moores Sheri L.
Published: April 2023

Live cell imaging of M2 macrophage mediated trogocytosis in adherent co-culture
Supplementary Table S3 from CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma
Authors: Flores Guillermo , Everett Joel H. , Boguslawski Elissa A. , Oswald Brandon M. , Madaj Zachary B. , Beddows Ian , Dikalov Sergey , Adams Marie , Klumpp-Thomas Carleen A. , Kitchen-Goosen Susan M. , Martin Scott E. , Caplen Natasha J. , Helman Lee J. , Grohar Patrick J.
Published: April 2023

Laboratory values
Supplementary Data from CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma
Authors: Flores Guillermo , Everett Joel H. , Boguslawski Elissa A. , Oswald Brandon M. , Madaj Zachary B. , Beddows Ian , Dikalov Sergey , Adams Marie , Klumpp-Thomas Carleen A. , Kitchen-Goosen Susan M. , Martin Scott E. , Caplen Natasha J. , Helman Lee J. , Grohar Patrick J.
Published: April 2023

Supplementary Table S2 and Supplementary Figures S1 to S10
Supplementary Figure 1. from The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA
Authors: Sugimoto Yohei , Katsumi Yoshiki , Iehara Tomoko , Kaneda Daisuke , Tomoyasu Chihiro , Ouchi Kazutaka , Yoshida Hideki , Miyachi Mitsuru , Yagyu Shigeki , Kikuchi Ken , Tsuchiya Kunihiko , Kuwahara Yasumichi , Sakai Toshiyuki , Hosoi Hajime
Published: April 2023

Supplementary Figure 1.
Table S1, S2 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
Authors: Makdasi Efi , Amsili Shira , Aronin Alexandra , Prigozhina Tatyana B. , Tzdaka Kobi , Gozlan Yosi Meir , Ben Gigi–Tamir Liat , Sagiv Jitka Yehudith , Shkedy Fanny , Shani Noam , Tykocinski Mark L. , Dranitzki Elhalel Michal
Published: April 2023

Table S1. Summary of the Toxicokinetic Parameters of CTLA4-FasL in mouse Plasma at the first injection (Day 1) and the third injection (Day 5) Table S2. Summary of the Pharmacokinetic parameters in a single dose of CTLA4-FasL in Cynomolgus monkey plasma
Figure S4 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL
Authors: Makdasi Efi , Amsili Shira , Aronin Alexandra , Prigozhina Tatyana B. , Tzdaka Kobi , Gozlan Yosi Meir , Ben Gigi–Tamir Liat , Sagiv Jitka Yehudith , Shkedy Fanny , Shani Noam , Tykocinski Mark L. , Dranitzki Elhalel Michal
Published: April 2023

Elevation of pro-inflammatory cytokines in CTLA4-FasL treated mice was prevented by dexamethasone
Table S3 from Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer
Authors: Al Amri Waleed S. , Allinson Lisa M. , Baxter Diana E. , Bell Sandra M. , Hanby Andrew M. , Jones Stacey J. , Shaaban Abeer M. , Stead Lucy F. , Verghese Eldo T. , Hughes Thomas A.
Published: April 2023

Somatic variants data
Supplementary Data from Extracellular Vesicle–Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity
Authors: Forterre Alexis V. , Wang Jing-Hung , Delcayre Alain , Kim Kyuri , Green Carol , Pegram Mark D. , Jeffrey Stefanie S. , Matin A.C.
Published: April 2023

Supplementary Figure S1 shows composition of the EVHB protein and making of EXO-DEPTS. Supplementary Figure S2 shows the size and proteins that characterize extracellular vesicles. Supplementary Figure S3 shows that the mRNA is inside the extracellular vesicles. Supplementary figure S4 shows that low doses of IVT EXO-DEPTs are ineffective. Supplementary Table S1 provides full names of abbreviations used in Figure 6.